UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
October 10, 2005
Date of Report (Date of earliest event reported)
ANTIGENICS INC
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| DELAWARE
|
|
000-29089
|
|
06-1562417 |
(State or other
jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.) |
| |
|
|
| 630 Fifth Avenue, Suite 2100 |
|
|
| New York, NY 10111
|
|
10111 |
| (Address of principal executive offices)
|
|
(Zip Code) |
212-994-8200
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
TABLE OF CONTENTS
Item 7.01 Regulation FD Disclosure
On October 10, 2005, Antigenics Inc. announced its preliminary survival data from its
Phase 3 metastatic melanoma trial. The full text of the press release issued in
connection with the announcement is being furnished as Exhibit 99.1 to this current
report on Form 8-K.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibit is furnished herewith:
| |
|
|
|
|
|
|
|
|
|
99.1 |
|
|
Press Release dated October 10, 2005 |